Advertisement

Ovarian Cancer

A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.

Aug 03, 2020

This Phase Ib study explored combination dosing of the allosteric MEK1/2 inhibitor cobimetinib and the ATP-competitive pan-AKT inhibitor ipatasertib.Patients with advanced solid tumors were enrolled t...

Computational-based identification and analysis of globally expressed differential genes in high-grade serous ovarian carcinoma cell lines.

Aug 03, 2020

Ovarian Cancer (OVCA) is the most occurring gynecological cancer worldwide, often diagnosed at a later stage and ultimate results in a high death rate. To overcome this serious health concern, it is i...

Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center.

Jul 30, 2020

Prior studies suggest that referral to genetic counseling and completion of genetic testing vary by race/ethnicity; however, the data are limited.We sought to evaluate patterns of genetic testing and ...

Circular RNA circRHOBTB3 inhibits ovarian cancer progression through PI3K/AKT signaling pathway.

Jul 30, 2020

Circular RNAs (circRNAs) have emerged as significant regulators in human cancers. We aimed to explore the functional role of circular RNA RHOBTB3 (circRHOBTB3) in ovarian cancer.The expression of circ...

Real-world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau.

Jul 30, 2020

Olaparib has been approved as an active and maintenance therapy for patients with platinum-sensitive, BRCA-mutated high-grade serous ovarian cancer (SOC). However, the efficacy and safety data is lack...

Nucleosome Assembly Protein 1-Like 3 Enhances Cisplatin Resistance of Ovarian Cancer Cell by Activating Transforming Growth Factor-Beta Pathway.

Jul 27, 2020

Chemotherapy resistance is one of the main reasons for tumor-related death. In particular, ovarian cancer patients often acquire drug resistance after chemotherapy. In this study, we found that the hi...

Effect of delayed palliative chemotherapy on survival of patients with recurrent ovarian cancer.

Jul 27, 2020

For patients with recurrent ovarian cancer, the goals of chemotherapy include palliation of disease-related symptoms with minimum treatment-related side effects. However, there is currently a paucity ...

Nuclear IGF1R interact with PCNA to preserve DNA replication after DNA-damage in a variety of human cancers.

Jul 27, 2020

Nuclear IGF1R has been linked to poor outcome in cancer. We recently showed that nuclear IGF1R phosphorylates PCNA and increases DNA damage tolerance. In this paper we aimed to describe this mechanism...

Radiotherapy in women with epithelial ovarian cancer: historical role, current advances, and indications.

Jul 23, 2020

Epithelial ovarian cancer (OC) is known to be a neoplasm responsive to radiotherapy (RT). Nevertheless, the role of RT in the management of this disease represent a topic of controversy, and the indic...

Blood natural killer cells during treatment in recurrent ovarian cancer.

Jul 23, 2020

Recent research indicated favorable prognostic impact of intratumoral natural killer (NK) cells in ovarian carcinoma (OC). The role of NK cells during chemotherapy in OC is unknown. We investigated im...

LncRNA TMPO-AS1 promotes LCN2 transcriptional activity and exerts oncogenic functions in ovarian cancer.

Jul 23, 2020

Ovarian cancer remains the sixth most frequently occurring cancer in women worldwide. Long noncoding RNAs (lncRNAs) are capable of regulating gene expression, and thus, participating in a wide range o...

Ascites-induced compression alters the peritoneal microenvironment and promotes metastatic success in ovarian cancer.

Jul 20, 2020

The majority of women with recurrent ovarian cancer (OvCa) develop malignant ascites with volumes that can reach > 2 L. The resulting elevation in intraperitoneal pressure (IPP), from normal va...

Potential of platinum-resensitization by Wnt signaling modulators as treatment approach for epithelial ovarian cancer.

Jul 20, 2020

Canonical Wnt/ β-catenin pathway is one mechanism being activated in platinum-resistant epithelial ovarian cancer (EOC). Detecting potential targets for Wnt pathway modulation as a putative future th...

MAGI2-AS3 suppresses MYC signaling to inhibit cell proliferation and migration in ovarian cancer through targeting miR-525-5p/MXD1 axis.

Jul 20, 2020

Ovarian cancer (OV) is one of the most lethal gynecological malignance in females, and usually diagnosed at advanced stages. Long noncoding RNAs (lncRNAs) exhibit their crucial functions in modulatory...

Potentially functional variants in nucleotide excision repair pathway genes predict platinum treatment response of Chinese ovarian cancer patients.

Jul 16, 2020

Acquired platinum resistance impedes successful treatment of epithelial ovarian cancer (EOC), and this resistance may be associated with inherited DNA damage-repair response. In the present study, we ...

Preclinical studies of a novel snake venom-derived recombinant disintegrin with antitumor activity: A review.

Jul 16, 2020

Snake venoms consist of a complex mixture of many bioactive molecules. Among them are disintegrins, which are peptides without enzymatic activity, but with high binding affinity for integrins, transme...

Accuracy of peritoneal carcinomatosis extent diagnosis by initial FDG PET CT in epithelial ovarian cancer: a multicentre study of the FRANCOGYN research group.

Jul 16, 2020

Peritoneal carcinomatosis extent in ovarian cancer is difficult to evaluate by imaging techniques even though it determines the surgical complexity and survival. The aim of this study was to estimate ...

Epithelial/mesenchymal heterogeneity of high-grade serous ovarian carcinoma samples correlates with miRNA let-7 levels and predicts tumor growth and metastasis.

Jul 13, 2020

Patient-derived samples present an advantage over current cell line models of high grade serous ovarian cancer (HGSOC) that are not always reliable and phenotypically faithful models of in vivo HGSOC....

Successful Treatment of Patients with Refractory High-Grade Serous Ovarian Cancer with GOPC-ROS1 Fusion Using Crizotinib: A Case Report.

Jul 13, 2020

Recently, multiple poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated excellent efficacy among patients with ovarian cancer with or without BRCA mutations. However, alternative therapeut...

Exploring the In Vivo and In Vitro Anticancer Activity of Rhenium Isonitrile Complexes.

Jul 09, 2020

The established platinum-based drugs form covalent DNA adducts to elicit their cytotoxic response. Although they are widely employed, these agents cause toxic side-effects and are susceptible to cance...

SUBSPECIALTIES

Advertisement